GlaxoSmithKline (GSK), a research-based pharmaceutical and healthcare company, has announced that Julian Heslop is to retire as chief financial officer (CFO) and executive director at the end of March 2011. Simon Dingemans will join as CFO designate and executive director effective 4 January 2011.
Dingemans joins from Goldman Sachs where he is currently managing director and partner. He has over 25 years of experience in investment banking, including most recently as leader of Goldman Sachs’ European merger and acquisition (M&A) business, and before that as head of UK investment banking. During this time he has built relationships and offered strategic advice across multiple industry sectors, including pharmaceuticals and consumer healthcare.
He has worked closely with GSK for many years, most recently helping to establish ViiV Healthcare, a specialist HIV company.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.